Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial12

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial1

Views

Views
July 20240
August 20240
September 20241
October 20240
November 20240
December 20240
January 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Spain1
 

Top cities views

Views
Madrid1